Sarcopenia Adversely Impacts Postoperative Complications Following Resection or Transplantation in Patients with Primary Liver Tumors

Journal of Gastrointestinal Surgery

Volumn 19, Issue 2, 2015, Pages 272-281

  Valero, Vicente ^a   Amini, Neda ^a   Spolverato, Gaya ^a   Weiss, Matthew J ^a   Hirose, Kenzo ^a   Dagher, Nabil N ^a   Wolfgang, Christopher L ^a   Cameron, Andrew A ^a   Philosophe, Benjamin ^a   Kamel, Ihab R ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Liver cancer; Liver surgery; Outcomes; Sarcopenia

Indexed keywords

ADULT; ADVERSE EFFECTS; AGED; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COMPLICATION; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INCIDENCE; INTRAHEPATIC BILE DUCT; LIVER NEOPLASMS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PSOAS MUSCLE; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK FACTOR; SARCOPENIA; SURVIVAL RATE;

ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HEPATECTOMY; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGAN SIZE; PSOAS MUSCLES; RADIOGRAPHY; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOPENIA; SURVIVAL RATE;

EID: 84925498026     PISSN: 1091255X     EISSN: 18734626     Source Type: Journal    
DOI: 10.1007/s11605-014-2680-4     Document Type: Article

References (50)

1. SEER Cancer Statistics Review, 1975–2011 [http://seer.cancer.gov/csr/1975_2011/]
2. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade.Ann Surg 2002, 236:397–406– discussion 406–7
3. Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, Holt C, Harlander-Locke M, Hong JC, Rana AR, Venick R, McDiarmid SV, Goldstein LI, Durazo F, Saab S, Han S, Xia V, Hiatt JR, Busuttil RW: The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center.Ann Surg 2013, 258:409–421.
4. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, Chen P, Busuttil RW: Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.Liver Transpl 2001, 7:1023–1033.
5. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA, Saab S, Tong MJ, Hiatt JR, Busuttil RW: Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center.Arch Surg 2011, 146:683–689.
6. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.Ann Surg 2005, 242:451–8– discussion 458–61
7. Meyer CG, Penn I, James L: Liver transplantation for cholangiocarcinoma: results in 207 patients.Transplantation 2000, 69:1633–1637.
8. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok ASF: Re-weighting the model for end-stage liver disease score components.Gastroenterology 2008, 135:1575–1581.
9. Nathan H, Schulick RD, Choti MA, Pawlik TM: Predictors of survival after resection of early hepatocellular carcinoma.Ann Surg 2009, 249:799–805.
10. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, Thiemann O, Papadopoulou D: Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine.Urology 1996, 48:373–378.
11. Buccheri G, Ferrigno D, Tamburini M: Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.Eur J Cancer 1996, 32A:1135–1141.
12. Reuben DB, Mor V, Hiris J: Clinical symptoms and length of survival in patients with terminal cancer.Arch Intern Med 1988, 148:1586–1591.
13. Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting.Cancer 1984, 53:2002–2007
14. List MA, Ritter-Sterr C, Lansky SB: A performance status scale for head and neck cancer patients.Cancer 1990, 66:564–569.
15. Khan RB, Sanford RA, Kun LE, Thompson SJ: Morbidity of second-look surgery in pediatric central nervous system tumors.Pediatr Neurosurg 2001, 35:225–229.
16. Sloan JA, Loprinzi CL, Laurine JA, Novotny PJ, Vargas-Chanes D, Krook JE, O’Connell MJ, Kugler JW, Tirona MT, Kardinal CG, Wiesenfeld M, Tschetter LK, Hatfield AK, Schaefer PL: A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index.J Clin Oncol 2001, 19:3539–3546.
17. Lang P-O, Michel J-P, Zekry D: Frailty syndrome: a transitional state in a dynamic process.Gerontology 2009, 55:539–549.
18. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, Holcombe SA, Wang SC, Segev DL, Sonnenday CJ: Sarcopenia and mortality after liver transplantation.Journal of the American College of Surgeons 2010, 211:271–278.
19. Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind J-FH, Kamel IR, Pawlik TM: Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies.J Gastrointest Surg 2013:1–10.
20. Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, Takenaga R, Devgan L, Holzmueller CG, Tian J, Fried LP: Frailty as a predictor of surgical outcomes in older patients.Journal of the American College of Surgeons 2010, 210:901–908.
21. Harimoto N, Shirabe K, Yamashita Y-I, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, Nishie A, Yamanaka T: Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma.Br J Surg 2013, 100:1523–1530.
22. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, Edil BH, Wolfgang CL, Schulick RD, Choti MA, Kamel I, Pawlik TM: Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis.HPB (Oxford) 2011, 13:439–446.
23. Reisinger KW, van Vugt JLA, Tegels JJW, Snijders C, Hulsewé KWE, Hoofwijk AGM, Stoot JH, Meyenfeldt Von MF, Beets GL, Derikx JPM, Poeze M: Functional Compromise Reflected by Sarcopenia, Frailty, and Nutritional Depletion Predicts Adverse Postoperative Outcome After Colorectal Cancer Surgery.Ann Surg 2014:1.
24. Silver JK, Baima J: Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes.Am J Phys Med Rehabil 2013, 92:715–727.
25. Debes C, Aissou M, Beaussier M: [Prehabilitation. Preparing patients for surgery to improve functional recovery and reduce postoperative morbidity].Ann Fr Anesth Reanim 2014, 33:33–40.
26. Santa Mina D, Clarke H, Ritvo P, Leung YW, Matthew AG, Katz J, Trachtenberg J, Alibhai SMH: Effect of total-body prehabilitation on postoperative outcomes: a systematic review and meta-analysis.Physiotherapy 2013.
27. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.Lancet Oncol 2008, 9:629–635.
28. Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, Makary M, Hirose K, Edil B, Choti MA, Herman J, Cameron JL, Wolfgang CL, Pawlik TM: Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma.J Gastrointest Surg 2012, 16:1478–1486.
29. Clavien PA, Camargo CA, Croxford R, Langer B, Levy GA, Greig PD: Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation.Ann Surg 1994, 220:109–120.
30. Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis.Nat Methods 2012, 9:671–675.
31. Dimick JB, Cowan JA, Knol JA, Upchurch GR: Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database.Arch Surg 2003, 138:185–191.
32. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM: Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients.Ann Surg 2009, 250:440–448.
33. Nathan H, Cameron JL, Choti MA, Schulick RD, Pawlik TM: The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship.Journal of the American College of Surgeons 2009, 208:528–538.
34. Mavros MN, de Jong M, Dogeas E, Hyder O, Pawlik TM: Impact of complications on long-term survival after resection of colorectal liver metastases.Br J Surg 2013, 100:711–718.
35. Reddy SK, Barbas AS, Turley RS, Gamblin TC, Geller DA, Marsh JW, Tsung A, Clary BM, Lagoo-Deenadayalan S: Major liver resection in elderly patients: a multi-institutional analysis.Journal of the American College of Surgeons 2011, 212:787–795.
36. Saxton A, Velanovich V: Preoperative frailty and quality of life as predictors of postoperative complications.Ann Surg 2011, 253:1223–1229.
37. Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM: Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer.Cancer 2008, 113:2205–2214.
38. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S: Sarcopenia as a prognostic factor among patients with stage III melanoma.Ann Surg Oncol 2011, 18:3579–3585.
39. Tan BHL, Birdsell LA, Martin L, Baracos VE, Fearon KCH: Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.Clin Cancer Res 2009, 15:6973–6979.
40. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU: Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.Journal of Clinical Oncology 2010, 28:340–347.
41. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB: Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.Ann Oncol 2010, 21:1594–1598.
42. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.Journal of Clinical Oncology 2010, 28:1054–1060.
43. Bonekamp D, Bonekamp S, Halappa VG, Geschwind J-FH, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR: Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.Eur J Radiol 2014, 83:487–496.
44. Bonekamp S, Bonekamp D, Geschwind J-FH, Corona-Villalobos CP, Reyes DK, Pawlik TM, Kamel IR: Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction.J Magn Reson Imaging 2013:n/a–n/a.
45. Bonekamp S, Halappa VG, Geschwind J-FH, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR: Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.Radiology 2013, 268:431–439.
46. Bonekamp S, Li Z, Geschwind J-FH, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR: Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.Radiology 2013, 268:420–430.
47. Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D, Pawlik TM, Diaz LA, Bhagat N, Eng J, Geschwind J-F, Kamel IR: Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival.Radiology 2013, 266:502–513.
48. Kostis WJ, Yankelevitz DF, Reeves AP, Fluture SC, Henschke CI: Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT.Radiology 2004, 231:446–452.
49. Wormanns D, Kohl G, Klotz E, Marheine A, Beyer F, Heindel W, Diederich S: Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility.Eur Radiol 2004, 14:86–92.
50. Revel M-P, Bissery A, Bienvenu M, Aycard L, Lefort C, Frija G: Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable?Radiology 2004, 231:453–458.